Curcumin-based nanotherapeutics - Laila Pharmaceuticals

Drug Profile

Curcumin-based nanotherapeutics - Laila Pharmaceuticals

Alternative Names: LP-001-09; LP-002-09; LP-004-09; LP-005-09; LP-013-09; LPCVD; LPD-1050; LPG-1030-I; LPG-1030-S; LPMD; LPO-1010-AM; LPO-1010-CA; LPO-1010-CSR; LPO-1010-DR; LPO-1010-UV

Latest Information Update: 30 Mar 2016

Price : $50

At a glance

  • Originator Laila Pharmaceuticals
  • Class Anti-ischaemics; Antihistamines; Antivirals; Catechols; Chemopreventatives; Nonsteroidal anti-inflammatories; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Antioxidants; Cyclo-oxygenase 2 inhibitors; HIV integrase inhibitors; Immunosuppressants; Mast cell stabilisers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Age-related macular degeneration; Cataracts; Psoriasis
  • Preclinical Cardiovascular disorders; Central serous chorioretinopathy; Diabetes mellitus; Diabetic retinopathy; Inflammatory bowel diseases; Irritable bowel syndrome; Uveitis
  • No development reported Allergic conjunctivitis; Alzheimer's disease; HIV infections; Osteoarthritis; Stomatitis

Most Recent Events

  • 16 Mar 2016 Clinical development for Cataracts is ongoing in India
  • 16 Mar 2016 No recent reports on development identified - Phase-II for Allergic conjunctivitis in India (Ophthalmic)
  • 16 Mar 2016 No recent reports on development identified - Phase-II for Stomatitis in India (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top